Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa
Author:
Publisher
Elsevier BV
Subject
Genetics,Molecular Biology,Molecular Medicine
Reference18 articles.
1. Fabry's disease;Zarate;Lancet,2008
2. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease;Eng;N. Engl. J. Med.,2001
3. Enzyme replacement therapy in Fabry disease: a randomized controlled trial;Schiffmann;JAMA,2001
4. Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in Fabry disease;Lenders;Drugs,2021
5. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta;Linthorst;Kidney Int.,2004
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Was ist gesichert in der Therapie von Morbus Fabry?;Die Innere Medizin;2024-08-06
2. Fabry nephropathy: a treatable cause of chronic kidney disease;Rare Disease and Orphan Drugs Journal;2024-07-11
3. Binding Promiscuity of Therapeutic Factor VIII;Thrombosis and Haemostasis;2024-07-01
4. Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease;Frontiers in Genetics;2024-04-12
5. Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study – determination of immunogenicity;Journal of Medical Genetics;2024-04-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3